New hope for advanced prostate cancer: TRC003 drug trial launches
NCT ID NCT07567521
First seen May 06, 2026 · Last updated May 06, 2026
Summary
This early-stage trial tests a new drug called TRC003 in 90 men with a type of advanced prostate cancer that has stopped responding to standard treatments. The study aims to check the drug's safety and how well it shrinks tumors. Participants will receive up to 6 cycles of TRC003 at different doses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences, Shanxi Hospital
Taiyuan, Shanxi, 030013, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fudan University Shanghai Cancer Center
Shanghai, 200032, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.